Contraline Closes $10.7 Million Series A Financing to Become a Clinical Stage Company
Company Receives Ethics Approval in Australia to Conduct First-In-Human Study to Assess Safety of ADAM™ Male Contraceptive as Alexander W. Pastuszak MD, PhD, Joins as Acting Chief Medical Officer.